raloxifene hydrochloride has been researched along with phosphorus in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bekele, A; Bendele, R; Bensch, WR; Black, LJ; Cullinan, GJ; Kauffman, RF; Magee, DE; Rowley, ER; Sato, M; Williams, DC | 1 |
| Colao, A; Lombardi, G; Mastrantonio, P; Morelli, M; Nappi, C; Orio, F; Palomba, S; Pellicano, M; Russo, T; Zullo, F | 1 |
| Cantor, P; Deal, C; Eriksen, EF; Glass, EV; Krege, JH; Myers, SL; Omizo, M; Schwartz, EN; Wang, J | 1 |
| Narayana Murthy, PS; Sengupta, S; Sharma, S; Singh, MM | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Aydin, K; Guclu, F; Hekimsoy, Z; Kafesciler, SO; Kirmaz, C; Ozmen, B | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M | 1 |
| Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Slinin, Y | 1 |
| Braga, S; Cannata-Andía, JB; Carrillo-López, N; Fernández-Coto, T; López-Hernández, F; Lopez-Novoa, JM; Naves-Díaz, M; Rodríguez-Rodríguez, A | 1 |
| Fukagawa, M; Itoh, K; Kawanishi, H; Matsushita, K; Moriishi, M; Tanaka, M | 1 |
| Cintra, LT; Dezan-Júnior, E; Dornelles, RC; Ervolino, E; Gomes-Filho, JE; Lodi, CS; Sivieri-Araújo, G; Wayama, MT; Yamanari, GH | 1 |
| Farbodara, T; Haghverdi, F; Mortaji, S; Saidi, N; Soltani, P | 1 |
| Dayyani, L; Minaiyan, M; Varshosaz, J | 1 |
| Kitade, M; Nagata, M; Shioyama, M; Takasugi, S; Yamaji, T | 1 |
6 trial(s) available for raloxifene hydrochloride and phosphorus
| Article | Year |
|---|---|
Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Topics: Adult; Body Mass Index; Bone and Bones; Bone Density; Calcium; Delayed-Action Preparations; Female; Femur; Humans; Leiomyoma; Leuprolide; Lumbar Vertebrae; Middle Aged; Osteoporosis; Phosphorus; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2002 |
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Collagen; Collagen Type I; Creatine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Kidney Function Tests; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Phosphorus; Procollagen; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome; Uric Acid; Vomiting | 2005 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Topics: Amino Acids; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Cytokines; Female; Humans; Interleukin-6; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha; Vitamin D | 2007 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine | 2008 |
Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
Topics: Administration, Oral; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
8 other study(ies) available for raloxifene hydrochloride and phosphorus
| Article | Year |
|---|---|
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; Calcium; Cholesterol; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Estrogen Antagonists; Ethinyl Estradiol; Female; Hypertrophy; Ovariectomy; Phosphorus; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Triglycerides; Uterus | 1994 |
Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Topics: Animals; Apoptosis; Benzopyrans; Bone Density; Bone Marrow Cells; Bone Resorption; Calcium; Cell Differentiation; Cells, Cultured; Female; Lumbar Vertebrae; Mice; Mice, Inbred BALB C; Organ Size; Osteoclasts; Ovariectomy; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Stem Cells; Transforming Growth Factor beta; Transforming Growth Factor beta3; Uterus | 2006 |
Serum calcium, phosphorus and cardiovascular events in post-menopausal women.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Phosphorus; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.
Topics: Animals; Atrophy; Bone Density Conservation Agents; Calcitriol; Calcium; Cholesterol; Chronic Disease; Estradiol; Estrogens; Female; Hyperplasia; Kidney Diseases; Mammary Glands, Animal; Organ Size; Parathyroid Hormone; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tibia; Uterus | 2010 |
Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
Topics: Absorptiometry, Photon; Aged; Asian People; Bone Density; Bone Density Conservation Agents; Calcium; Case-Control Studies; Collagen Type I; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Renal Dialysis; Severity of Illness Index; Time Factors | 2011 |
Raloxifene modulates regulators of osteoclastogenesis and angiogenesis in an oestrogen deficiency periapical lesion model.
Topics: Alkaline Phosphatase; Animals; Biomarkers; Calcium; Disease Models, Animal; Estradiol; Female; Immunohistochemistry; Mandible; Neovascularization, Physiologic; Organ Size; Osteoclasts; Osteogenesis; Ovariectomy; Periapical Periodontitis; Phosphorus; Raloxifene Hydrochloride; Rats; Rats, Wistar | 2015 |
Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Biological Availability; Bone Density Conservation Agents; Calcium; Female; Maleates; Microscopy, Electron, Scanning; Nanoparticles; Osteoporosis; Ovariectomy; Phosphorus; Polyethylenes; Raloxifene Hydrochloride; Rats, Wistar; Solubility; Technology, Pharmaceutical | 2018 |
Involvement of estrogen in phosphorus-induced nephrocalcinosis through fibroblast growth factor 23.
Topics: Animals; Aorta; Bone Density; Calcium; Disease Models, Animal; Estrogens; Female; Fibroblast Growth Factors; Nephrocalcinosis; Ovariectomy; Phosphorus; Pyrimidines; Raloxifene Hydrochloride; Rats; Receptor, Fibroblast Growth Factor, Type 1 | 2020 |